A pooled analysis has been published of two cohorts from the phase I dose-expansion JAVELIN Solid Tumor study, which tested the anti-PDL1 antibody avelumab in 249 patients with locally advanced or metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy. Of 161 patients with ≥ 6-month follow-up data, 6% had a complete and 11% had a partial response. Serious adverse events related to treatment with avelumab occurred in 8% of 249 patients; one treatment-related death owing to pneumonitis occurred.